Single-dose Versus 3-day Antimicrobial Prophylaxis in Transurethral Resection or Photoselective Vaporization of the Prostate: A Multicenter, Randomized, Placebo Controlled Trial (CITrUS Trial)
In this randomized trial of transurethral prostate surgery patients, 11.0% of those on single-dose AMP and 8.5% on 3-d AMP were diagnosed with UTIs. The smaller than planned sample size precludes a definite interpretation favoring either group. Diagnoses of UTIs based on symptoms and bacteriuria reduced the overall rates and group differences.
Authors
- Peter Ardelt
- Scott I. Merz
- Benjamin Speich (ORCID: https://orcid.org/0000-0002-3301-8085)
- Nicole Bruni (ORCID: https://orcid.org/0000-0001-9634-0701)
- Kathrin Bausch (ORCID: https://orcid.org/0000-0002-6253-0854)
- Stephen Wyler
- Lukas Prause (ORCID: https://orcid.org/0000-0002-1563-3543)
- Andreas F. Widmer (ORCID: https://orcid.org/0000-0002-7661-5824)
- Hans‐Helge Seifert (ORCID: https://orcid.org/0000-0003-1443-9316)
- D. Vogt (ORCID: https://orcid.org/0000-0002-0668-5675)
- Thomas Hermanns
- Lars G. Hemkens (ORCID: https://orcid.org/0000-0002-3444-1432)
- Piet Bossard
- Christian Engesser (ORCID: https://orcid.org/0000-0002-5816-9808)
- Maciej Kwiatkowski
- Svetozar Subotic
- Maeve Dreher
Institutions
- University of Basel (CH)
- University of Zurich (CH)
- University Hospital of Basel (CH)
- Klinikum Braunschweig (DE)
- Solothurner Spitäler (CH)
- St. Claraspital (CH)
- Kantonsspital Aarau (CH)
Publication Details
- Journal
- European Urology Focus
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1016/j.euf.2025.08.009
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung